Long acting injectable antiretroviral therapy is reshaping the HIV treatment landscape. A landmark randomized clinical trial published in the New England Journal of Medicine in February 2026 provides the strongest evidence to date that monthly injectable therapy can significantly improve outcomes for people with HIV who struggle with adherence to daily oral medication.
The LATITUDE trial, led by Aadia I. Rana and colleagues, demonstrates that monthly injections of long acting cabotegravir plus rilpivirine reduce the risk of regimen failure compared with standard oral antiretroviral therapy in individuals with documented adherence challenges. An accompanying editorial by Joshua A. Barocas explores the broader implications, shifting the conversation from efficacy to access.
This article breaks down the trial results, explains what they mean for patients and providers, and discusses why implementation may be the most important next step in advancing HIV care.
Over the past three decades, antiretroviral therapy has transformed HIV from a fatal disease into a manageable chronic condition. Modern fixed dose oral regimens are safe, potent, and generally well tolerated. However, viral suppression in the United States remains at approximately 67 percent.
Many people living with HIV face structural and behavioral barriers that make daily pill taking difficult. These include:
For individuals who cannot consistently adhere to daily medication, viral suppression can remain out of reach. Ongoing viremia increases the risk of disease progression and HIV transmission.
Long acting injectable therapy offers an alternative model. Instead of daily pills, treatment is administered monthly or every two months in a clinical setting. This approach shifts adherence from a daily responsibility to a scheduled health care visit, potentially reducing the burden on patients.
In 2021, the US Food and Drug Administration approved long acting injectable cabotegravir plus rilpivirine for people with HIV who were already virologically suppressed on oral therapy. Earlier phase 3 trials such as ATLAS and FLAIR showed that injectable therapy was noninferior to oral regimens in stable patients.
However, those trials largely excluded individuals with active viremia or documented adherence problems. As a result, guidelines limited use to patients with sustained viral suppression.
Observational studies suggested that injectable therapy might benefit people who struggle with adherence, but randomized evidence was lacking. The LATITUDE trial was designed to fill this gap.
The trial, formally known as the ACTG A5359 LATITUDE study, was a phase 3, open label, multicenter randomized clinical trial conducted across 33 sites in the United States. It was funded by the National Institute of Allergy and Infectious Diseases.
A total of 453 participants with HIV and documented adherence challenges were enrolled. Nonadherence was defined as persistent HIV RNA above 200 copies per milliliter or loss to follow up despite an active prescription for antiretroviral therapy.
Participants first entered a 24 week phase that included:
This step was designed to help participants achieve viral suppression before randomization.
A total of 306 participants achieved sufficient viral suppression and were randomized:
The primary outcome was regimen failure, defined as confirmed virologic failure or permanent discontinuation of the assigned treatment.
Randomization was stopped early due to demonstrated superiority of the injectable regimen.
The trial population reflected many of the social determinants associated with poor HIV outcomes:
Participants also faced economic instability, mental health challenges, and substance use issues. This demographic profile makes the findings particularly relevant to populations often underrepresented in clinical trials.
After a median follow up of 48 weeks, the results were striking.
The cumulative incidence of regimen failure at week 48:
The between group difference was negative 18.4 percentage points, which was statistically significant.
In simple terms, nearly twice as many participants experienced treatment failure with oral therapy compared with monthly injections.
Virologic failure was also significantly lower in the injectable group:
The difference in cumulative incidence of virologic failure at week 48 was negative 21.4 percentage points.
Treatment related failure also favored the injectable regimen by nearly 19 percentage points.
These consistent findings across primary and secondary outcomes strengthen the evidence that long acting injectable therapy is superior to standard oral therapy in this high risk population.
Safety outcomes were similar between groups.
Injection site reactions were common, affecting 60 percent of participants receiving injections. However, most reactions were mild, and only two participants discontinued treatment because of injection site issues.
Two deaths occurred in the injectable group, both deemed unrelated to the study medication.
Overall, the safety profile was consistent with previous studies of cabotegravir and rilpivirine.
Six participants in the injectable group experienced virologic failure. Notably:
Lower early drug trough concentrations were observed in some cases, suggesting that pharmacokinetic factors may contribute to breakthrough viremia in certain individuals.
Importantly, viral suppression was re achieved in most cases after switching back to oral therapy.
In an accompanying editorial, Joshua A. Barocas emphasizes that pharmacologic efficacy is only part of the equation.
The trial participants were able to engage with health care sufficiently to enroll and attend visits. Many individuals with the most severe barriers to care remain outside traditional systems.
Barocas argues that realizing the full benefit of long acting therapy will require:
The key insight is that adherence is often a delivery problem rather than a patient problem. Long acting injectable therapy reframes HIV treatment by shifting responsibility from daily self management to structured care delivery.
The LATITUDE trial challenges the long standing requirement that patients must be fully suppressed before starting injectable therapy.
A subgroup of participants began injections with detectable viremia, yet overall outcomes still strongly favored the injectable regimen.
This opens the door to broader use of direct to inject strategies, particularly for individuals with repeated oral treatment failure due to adherence challenges.
Future guidelines may incorporate long acting therapy earlier in the treatment pathway for selected patients.
Reducing regimen failure has implications beyond individual patient outcomes.
Improved viral suppression:
Populations disproportionately affected by HIV, including Black and Hispanic communities and individuals experiencing housing instability, may benefit substantially from expanded access to injectable therapy.
Despite encouraging results, several questions remain:
Ongoing and future trials will help clarify these issues.
The LATITUDE trial represents a pivotal moment in HIV care. Monthly injections of long acting cabotegravir plus rilpivirine significantly reduced regimen failure compared with standard oral therapy in people facing adherence challenges.
The evidence supports expanding the use of injectable antiretroviral therapy beyond narrowly defined populations with stable viral suppression. However, translating clinical efficacy into real world impact will depend on access, infrastructure, and policy decisions.
Long acting therapy does more than simplify dosing. It challenges traditional assumptions about adherence and reframes HIV treatment as a system level responsibility.
If health systems, policymakers, and insurers rise to the challenge, this innovation could play a major role in reducing disparities and accelerating progress toward ending the HIV epidemic.
Rana AI et al. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. New England Journal of Medicine. 2026;394:858 to 871.
Barocas JA. From Efficacy to Access in Long Acting HIV Therapy. New England Journal of Medicine. 2026;394:920 to 922.
This blog post is for educational and informational purposes only and does not constitute medical advice. Individuals should consult qualified health care professionals regarding diagnosis, treatment options, and personal medical decisions. Clinical decisions should be based on a full evaluation of each patient and current clinical guidelines.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.